Company Description
AbCellera Biologics Inc. builds an engine for antibody drug discovery and development.
Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies.
The company’s preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.
It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners.
The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
| Country | Canada |
| Founded | 2012 |
| IPO Date | Dec 11, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 586 |
| CEO | Carl Hansen |
Contact Details
Address: 2215 Yukon Street Vancouver, BC V5Y 0A1 Canada | |
| Phone | 604 559 9005 |
| Website | abcellera.com |
Stock Details
| Ticker Symbol | ABCL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $20.00 |
| CIK Code | 0001703057 |
| CUSIP Number | 00288U106 |
| ISIN Number | CA00288U1066 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Carl L.G. Hansen Ph.D. | Chief Executive Officer, President and Chairperson |
| Andrew Booth M.B.A. | Chief Financial Officer |
| Dr. Veronique Lecault Ph.D. | Chief Operating Officer and Director |
| Tryn T. Stimart Esq., J.D., M.Sc. | Chief Legal Officer, CCO, Compliance Officer, Corporate Secretary and Privacy Officer |
| Marcie Thiessen CPA, CGA | Senior Director of Finance and Accounting |
| Dr. Ester Falconer Ph.D. | Chief Technology Officer |
| Kathleen Reid B.A. | Head of Corporate Communications |
| Graham Craig M.Sc. | Director of Corporate Development |
| Murray McCutcheon Ph.D. | Senior Vice President of Partnering |
| Neil Aubuchon B.A., M.B.A. | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 4, 2024 | 10-Q | Quarterly Report |
| Nov 4, 2024 | 8-K | Current Report |
| Oct 9, 2024 | SCHEDULE 13G/A | Filing |
| Aug 6, 2024 | 10-Q | Quarterly Report |
| Aug 6, 2024 | 8-K | Current Report |
| Jun 13, 2024 | 8-K | Current Report |
| May 7, 2024 | 10-Q | Quarterly Report |
| May 7, 2024 | 8-K | Current Report |
| Apr 29, 2024 | ARS | Filing |
| Apr 29, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |